2015 American Transplant Congress
Patient Outcomes After Listing for Kidney Alone Transplantation in Potential Recipients Aged Over 70 Years
BackgroundLow likelihood of listing and subsequent deceased donor transplantation has previously been reported for the elderly with additional concerns about patient frailty, morbidity and mortality…2015 American Transplant Congress
Sevoflurane Based Anesthesia in Recipients Reduces 2 Year Acute Rejection in Living Donor Kidney Transplantation. Results from the VAPOR-Trial
IntroductionVolatile anesthetic agents like sevoflurane may protect against the ischemia and reperfusion injury (IRI) that is inevitable part of organ donation and transplantation. It is…2015 American Transplant Congress
Psychiatric Recommendations for Patients Pursing Kidney Transplantation
Transplant Institute, Henry Ford Health System, Detroit, MI.
Introduction: End-stage renal disease patients have high rates of psychiatric and cognitive pathologies. Despite this, renal transplant candidates do not routinely undergo comprehensive psychiatric evaluation.…2015 American Transplant Congress
The Role of Quantitative Assay of Urinary Decoy Cells as a Screening and Follow-Up Tool in Renal Transplant Recipients With Polyomavirus BK Infection
Polyomavirus BK nephropathy (BKVN) is an important infectious complication in kidney transplant patients. Urinary cytology is effective for early diagnosis of BKVN. However, quantitative assay…2015 American Transplant Congress
Change in Health-Related Quality of Life Between Evaluation for Kidney Transplantation and Transplantation
BACKGROUND: Kidney transplantation (KT) recipients have been found to have higher Health-related quality of life (HRQOL) than patients undergoing other forms of renal replacement therapy.…2015 American Transplant Congress
A Novel DSA Flow Cytometer Crossmatch (DSA-FXM) to Eliminate Ambiguous Auto- and Allo-FXM Results
Pathology, Stanford University, Palo Alto, CA.
Introduction:Though usually rejected on theoretical grounds, a positive Auto-FXM could result from either or both auto-reactive non-HLA or HLA-antibodies (Ab). Furthermore, a positive Auto-FXM serum…2015 American Transplant Congress
Outcomes of Treatment of Late Antibody-Mediated Rejection in Primary Renal Transplant Recipients – A Single Center Experience
Division of Nephrology and Transplant Institute, Henry Ford Hospital, Detroit, MI.
Background: Successful reversal of early post-transplant antibody mediated rejection (AMR) is well documented, but data on the results of treatment of late AMR are lacking.…2015 American Transplant Congress
Thymoglobulin Dosing Efficacy: The Role of ALC on Infection and Rejection
University of Minnesota, Minneapolis, MN.
There are varied Thymoglobulin® (Thymo) induction regimens accepted among transplant programs. Our center uses five doses of Thymo at 1.25mg/kg, yielding a total goal of…2015 American Transplant Congress
Effect of Everolimus on Cardiovascular Parameters in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
Background: Long-term exposure to calcineurin inhibitors (CNIs) contributes to an unfavorable cardiovascular (CV) risk profile, including inferior renal allograft function and premature graft loss with…2015 American Transplant Congress
Clinical Outcome of Patients With De Novo C1q Binding Donor-Specific HLA Antibodies After Renal Transplantation
A. Not all de novo donor-specific HLA antibodies (dnDSA) are causing immediate graft loss. The importance of complement-binding DSA was recently shown with a commercial…
American Transplant Congress abstracts